Intra-Cellular Therapies, Inc.

NasdaqGS ITCI

Intra-Cellular Therapies, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -62.91 M

Intra-Cellular Therapies, Inc. Free Cash Flow is USD -62.91 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 61.06% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Intra-Cellular Therapies, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -161.57 M, a 47.02% change year over year.
Intra-Cellular Therapies, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -304.98 M, a -19.60% change year over year.
Intra-Cellular Therapies, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -255.00 M, a -29.82% change year over year.
Intra-Cellular Therapies, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -196.43 M, a -59.05% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGS: ITCI

Intra-Cellular Therapies, Inc.

CEO	Dr. Sharon Mates Ph.D.
IPO Date	Jan. 7, 2014
Location	United States
Headquarters	430 East 29th Street
Employees	610
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Key trends

Past 5 years